Tocilizumab for ongoing antibody rejection after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial studies tocilizumab (a medicine that calms the immune system) to treat late or chronic active antibody-mediated rejection after a kidney transplant. It may help protect the transplanted kidney when the rejection has been confirmed by biopsy and you meet key safety and infection checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to take part by signing informed consent
- You had a single kidney transplant and it was at least 6 months ago
- Your biopsy shows late or chronic active antibody-mediated rejection (based on Banff 2022 criteria)
- Your kidney filtering (eGFR) is at least 20
- Your blood test shows EBV IgG positive (you’ve been exposed to EBV)
- You do not have active infections or other major exclusions (like active TB, hepatitis viruses by PCR, or current serious infection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.